Prostatic Pharmacokinetic and Pharmacodynamic Analysis of Ceftazidime: Dosing Strategy for Bacterial Prostatitis
The Journal of Clinical Pharmacology · 2025-01 · 65 (1) · 121-131
DOI: 10.1002/jcph.6119 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Pharmacology, online erschienen am 26.08.2024. Verfasst von Tetsushu Onita und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacotherapy, Hiroshima University, Hiroshima, Japan. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 39 Literaturangaben.
Abstract (Originalsprache)
This study aimed to develop a prostatic pharmacokinetic model of ceftazidime and suggest more effective dosing strategy for the bacterial prostatitis, based on a site‐specific pharmacokinetic and pharmacodynamic perspective. Subjects were prostatic hyperplasia patients prophylactically receiving a 0.5‐h infusion of 1.0 g or 2.0 g ceftazidime before transurethral resection of the prostate. Plasma and prostate samples were premeditatedly collected after the administration and the concentrations were measured by high‐performance liquid chromatography. The prostate tissue/plasma ratio in area under the drug concentration‐time curve was approximately 0.476. The prostatic population pharmacokinetic model incorporated creatinine clearance (CL cr ) into ceftazidime clearance was developed, and adequately predicted prostate tissue concentrations by diagnostic scatter plots and visual predictive checks. Aiming for a bactericidal target of 70% of time above minimum inhibitory concentration (T > MIC) in prostate tissue, 2.0 g twice daily achieved ≥90% expected probability against main pathogens like Escherichia coli and Proteus species in patients regardless of renal function (CL cr = 60 and 90 mL/min). However, since the expected probability of attaining the bactericidal target of 0.5‐h infusion dosing regimen did not achieve 90% against Pseudomonas aeruginosa in patients with CL cr = 60 and 90 mL/min, 4‐h infusion dosing regimen of 2.0 g three times daily (6 g/day) might be required for empirical treatment. Based on site‐specific simulations, the present study provides more effective dosing strategy for bacterial prostatitis.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Pharmacotherapy, Hiroshima University, Hiroshima, Japan.
- Department of Pharmacy, Shimane University Hospital, Izumo, Japan.
- Nakamura Urology Clinic, Owariasahi, Japan.
- Aichi Medical University School of Medicine, Nagakute, Japan.
- Asahi Rosai Hospital, Owariasahi, Japan.
ORCID-Profile: Tetsushu Onita, Kazuro Ikawa
Zitieren
APA
Onita, T., Nakamura, K., Nishikawa, G., Ishihara, N., Tamaki, H., Yano, T., Naora, K., Morikawa, N., & Ikawa, K. (2025). Prostatic Pharmacokinetic and Pharmacodynamic Analysis of Ceftazidime: Dosing Strategy for Bacterial Prostatitis. The Journal of Clinical Pharmacology, 65(1), 121-131. https://doi.org/10.1002/jcph.6119
Vancouver
Onita T, Nakamura K, Nishikawa G, Ishihara N, Tamaki H, Yano T, et al. Prostatic Pharmacokinetic and Pharmacodynamic Analysis of Ceftazidime: Dosing Strategy for Bacterial Prostatitis. The Journal of Clinical Pharmacology. 2025;65(1):121-131. doi:10.1002/jcph.6119
BibTeX
@article{Onita2025,
author = {Onita, Tetsushu and Nakamura, Kogenta and Nishikawa, Genya and Ishihara, Noriyuki and Tamaki, Hiroki and Yano, Takahisa and Naora, Kohji and Morikawa, Norifumi and Ikawa, Kazuro},
title = {Prostatic Pharmacokinetic and Pharmacodynamic Analysis of Ceftazidime: Dosing Strategy for Bacterial Prostatitis},
journal = {The Journal of Clinical Pharmacology},
year = {2025},
volume = {65},
number = {1},
pages = {121--131},
doi = {10.1002/jcph.6119}
}
EUVIMED